Bristol Myers Squibb Begins a $13.1 Billion Purchase of MyoKardia
Published
The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.
Full ArticlePublished
The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.
Full ArticleIn an announcement on Monday, Bristol Myers Squibb Co (NYSE: BMY) said it will invest £10 billion to acquire MyoKardia Inc..